Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CCEL Stock Forecast 2026-2027
$3.73
Current Price
$30.05M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CCEL Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CCEL Price Momentum
+2.5%
1 Week Change
+17.3%
1 Month Change
-32.5%
1 Year Change
+8.4%
Year-to-Date Change
-41.3%
From 52W High of $6.35
+37.1%
From 52W Low of $2.72
📊 TOP ANALYST CALLS
Did CCEL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cryo-Cell is one of their latest high-conviction picks.
Latest CCEL Stock Price Targets & Analyst Predictions
CCEL has shown a year-to-date change of 8.4% and a 1-year change of -32.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CCEL. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CCEL Analyst Ratings
0
Buy
1
Hold
0
Sell
CCEL Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.73
Latest CCEL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CCEL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 20, 2025 | Maxim Group | Allen Klee | Hold | Downgrade | $N/A |
| Mar 4, 2025 | Maxim Group | Allen Klee | Buy | Maintains | $8.50 |
| Aug 29, 2022 | Maxim Group | Allen Klee | Buy | Initiates | $12.00 |
Cryo-Cell International Inc. (CCEL) Competitors
The following stocks are similar to Cryo-Cell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cryo-Cell International Inc. (CCEL) Financial Data
Cryo-Cell International Inc. has a market capitalization of $30.05M with a P/E ratio of 475.0x. The company generates $31.57M in trailing twelve-month revenue with a -7.7% profit margin.
Revenue growth is -2.3% quarter-over-quarter, while maintaining an operating margin of -50.6% and return on equity of +13.1%.
Valuation Metrics
Market Cap
$30.05M
Enterprise Value
$38.31M
P/E Ratio
475.0x
PEG Ratio
46.6x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
-2.3%
Gross Margin
+77.9%
Operating Margin
-50.6%
Net Margin
-7.7%
EPS Growth
-2.8%
Financial Health
Cash/Price Ratio
+11.0%
Current Ratio
0.6x
Debt/Equity
-0.6x
ROE
+13.1%
ROA
+0.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cryo-Cell International Inc. (CCEL) Business Model
About Cryo-Cell International Inc.
What They Do
Biotechnology company specializing in cord blood banking.
Business Model
Cryo-Cell International Inc. generates revenue by offering cord blood and tissue banking services, allowing families to store umbilical cord blood and tissue at childbirth for potential future medical use. This service appeals to parents looking to protect their children's health against various genetic diseases and blood disorders, creating a recurring income stream through service fees.
Additional Information
Based in Oldsmar, Florida, Cryo-Cell is a key player in the biotechnology sector, focusing on innovation and quality control. The company is actively involved in the advancing field of regenerative medicine and aims to expand its scientific capabilities and service offerings.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
72
CEO
Mr. David I. Portnoy
Country
United States
IPO Year
1994
Website
www.cryo-cell.comCryo-Cell International Inc. (CCEL) Latest News & Analysis
Latest News
Quick Summary
Cryo-Cell International, Inc. received a notice from NYSE American regarding non-compliance with listing standards. This may impact the company's stock status.
Why It Matters
Cryo-Cell International's non-compliance with NYSE American listing standards could lead to delisting risks, affecting share price and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cryo-Cell International, Inc. reported fiscal 2025 revenues of $31.6 million, slightly down from $32.0 million in fiscal 2024, with $31.4 million from processing and storage fees.
Why It Matters
Cryo-Cell's slight revenue decline signals potential challenges in growth or market demand, impacting investor confidence and valuation in the stem cell banking sector.
Source: Business Wire
Market Sentiment:
Neutral
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results
5 months ago
Quick Summary
Cryo-Cell International reported Q3 2025 revenues of $7.83 million, down 3% from $8.07 million in Q3 2024. Further financial details were not disclosed in the excerpt.
Why It Matters
Cryo-Cell's Q3 revenue decline signals potential challenges in growth and demand, which may affect investor confidence and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cryo-Cell International (NYSE: CCEL) will not declare a quarterly cash dividend for Q3 fiscal 2025 due to lower-than-expected profitability; future dividend reinstatement is uncertain.
Why It Matters
Cryo-Cell's decision to suspend its quarterly cash dividend signals reduced profitability, which may concern investors about the company's financial health and future growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results
8 months ago
Quick Summary
Cryo-Cell International reported Q2 2025 revenues of $7.9 million, down 1% from $8.0 million in Q2 2024. The majority of revenue came from core operations at $7.8 million.
Why It Matters
Cryo-Cell's slight revenue decline may indicate challenges in growth or market demand, potentially impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cryo-Cell International, Inc. (CCEL) will pay a reduced quarterly cash dividend of $0.15 per share due to the current economic environment. Shareholders of record will be eligible.
Why It Matters
Cryo-Cell's decision to reduce its quarterly dividend signals potential cash flow issues, impacting investor confidence and potentially affecting the stock price negatively.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CCEL Stock
What is Cryo-Cell International Inc.'s (CCEL) stock forecast for 2026?
Analyst forecasts for Cryo-Cell International Inc. (CCEL) are not currently available. The stock is trading at $3.73.
Is CCEL stock a good investment in 2026?
According to current analyst ratings, CCEL has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CCEL stock?
Price predictions from Wall Street analysts for CCEL are not currently available. The stock is trading at $3.73.
What is Cryo-Cell International Inc.'s business model?
Cryo-Cell International Inc. generates revenue by offering cord blood and tissue banking services, allowing families to store umbilical cord blood and tissue at childbirth for potential future medical use. This service appeals to parents looking to protect their children's health against various genetic diseases and blood disorders, creating a recurring income stream through service fees.
What is the highest forecasted price for CCEL Cryo-Cell International Inc.?
Price targets from Wall Street analysts for CCEL are not currently available. The stock is trading at $3.73.
What is the lowest forecasted price for CCEL Cryo-Cell International Inc.?
Price targets from Wall Street analysts for CCEL are not currently available. The stock is trading at $3.73.
What is the overall CCEL consensus from analysts for Cryo-Cell International Inc.?
The overall analyst consensus for CCEL is neutral. Out of 1 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are CCEL stock price projections?
Stock price projections, including those for Cryo-Cell International Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 9, 2026 3:12 PM UTC